Gout Medical Services in China

Gout is a common, painful form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and soft tissues, resulting from chronic hyperuricemia—serum uric acid levels exceeding 6.8 mg/dL. It predominantly affects the first metatarsophalangeal joint (podagra), but can involve ankles, knees, wrists, fingers, and elbows. Pathogenesis involves impaired renal urate excretion (accounting for ~90% of cases) or, less commonly, overproduction due to enzymatic defects (e.g., PRPS hyperactivity, HGPRT deficiency), dietary purine excess, or metabolic comorbidities. Urate crystal deposition triggers NLRP3 inflammasome activation, leading to IL-1β–driven neutrophil infiltration, synovial inflammation, and acute flares lasting 3–10 days untreated. Chronic gout may progress to tophaceous deposits, joint erosion, and irreversible damage if uncontrolled. Epidemiologically, gout affects approximately 1–4% of adults globally, with rising prevalence in China—estimated at 1.1–3.2% among adults aged ≥18 years—and higher incidence in men (peak onset 40–50 years) and postmenopausal women. Key modifiable risk factors include obesity (BMI ≥25 kg/m²), excessive alcohol intake (especially beer and spirits), high-purine diets (red meat, shellfish, organ meats), fructose-sweetened beverages, hypertension, chronic kidney disease (CKD stages 2–4), diuretic use (e.g., thiazides), and metabolic syndrome. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and family history. Gout significantly impairs quality of life: recurrent flares cause severe pain, functional limitation, work absenteeism, sleep disruption, anxiety, and depression. Patients often report reduced mobility, social withdrawal, and diminished participation in daily activities—even during intercritical periods. Untreated gout increases long-term cardiovascular risk (e.g., myocardial infarction, stroke) and accelerates CKD progression. Early diagnosis via clinical criteria (e.g., ACR/EULAR 2015 classification), serum uric acid testing, synovial fluid analysis (gold standard for crystal identification), and dual-energy CT (for tophus detection) is essential. Management requires a dual-phase strategy: rapid anti-inflammatory control of acute flares (NSAIDs, colchicine, or glucocorticoids), followed by long-term urate-lowering therapy (ULT) targeting serum uric acid <6.0 mg/dL (<5.0 mg/dL for tophaceous disease) using xanthine oxidase inhibitors (allopurinol, febuxostat) or uricosurics (lesinurad, benzbromarone where available). Lifestyle modification—including weight loss, low-purine diet, alcohol moderation, hydration, and avoidance of fasting or rapid weight loss—is foundational. Patient education on adherence, flare prophylaxis during ULT initiation, and comorbidity management is critical for sustainable outcomes.

Gout is a chronic, inflammatory arthropathy driven by hyperuricemia—elevated serum uric acid (sUA) concentrations exceeding the physiological solubility threshold of approximately 6.8 mg/dL—leading to monosodium urate (MSU) crystal deposition in joints, soft tissues, and kidneys. As a metabolic disorder frequently intersecting with insulin resistance, hypertension, chronic kidney disease (CKD), and cardiovascular disease, gout management falls under the purview of endocrinology due to its pathophysiological links with purine metabolism, renal handling of uric acid, and comorbid metabolic syndrome. Optimal treatment requires a stratified, phase-specific approach encompassing acute attack suppression, intercritical management, and long-term urate-lowering therapy (ULT) to prevent structural joint damage, tophi formation, and renal impairment.

Conservative treatment forms the cornerstone of gout care and must be initiated at diagnosis. Lifestyle modification is evidence-based and non-pharmacologic: patients are advised to limit high-purine foods (e.g., organ meats, shellfish, yeast extracts), avoid sugar-sweetened beverages and excessive alcohol—particularly beer and spirits—and maintain a healthy body weight through gradual, sustainable weight loss (≥5% body weight reduction improves sUA by ~0.5–1.0 mg/dL). Hydration should exceed 2 L/day to promote uric acid excretion and reduce nephrolithiasis risk. Patients with CKD or heart failure require individualized fluid targets. Dietary patterns such as the DASH (Dietary Approaches to Stop Hypertension) diet and Mediterranean diet demonstrate modest but clinically meaningful reductions in sUA and gout flares. Importantly, fasting and rapid weight loss are contraindicated, as they induce ketosis and transient hyperuricemia. Joint protection strategies—including temporary activity modification during flares and ergonomic assessment for occupational stressors—are integrated into comprehensive conservative care.

Pharmacotherapy is guided by disease phase and patient-specific factors including renal function, comorbidities, and flare frequency. For acute gout attacks, first-line agents include nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin or naproxen (if no contraindications), low-dose colchicine (1.2 mg followed by 0.6 mg one hour later, then 0.6 mg once or twice daily), or intra-articular or systemic glucocorticoids (e.g., oral prednisone 30–35 mg/day tapered over 7–10 days). IL-1 inhibitors (e.g., anakinra) are reserved for refractory cases or contraindications to conventional agents. Inter-critical management focuses on ULT initiation only after resolution of acute inflammation—typically ≥2 weeks post-flare—to avoid flare precipitation. First-line ULT is allopurinol, titrated gradually (starting at 100 mg/day in CKD stage 3+; 200–300 mg/day otherwise) to achieve and maintain sUA <5.0 mg/dL (target <4.0 mg/dL in patients with tophi or frequent flares). Febuxostat is an alternative xanthine oxidase inhibitor for allopurinol-intolerant or non-responsive patients, though cardiovascular safety requires careful evaluation. Uricosurics (e.g., probenecid, benzbromarone—available in China but not FDA-approved) enhance renal uric acid excretion and are preferred in underexcretors (fractional excretion of uric acid >5–10%) with preserved renal function. Lesinurad is used adjunctively with xanthine oxidase inhibitors in refractory cases. All ULT regimens mandate concomitant anti-inflammatory prophylaxis (colchicine 0.5–0.6 mg once or twice daily for ≥6 months) to mitigate flare risk during urate-lowering.

Surgical intervention is rarely indicated but plays a defined role in advanced gout. Tophaceous gout with large, ulcerating, infected, or mechanically disabling tophi may necessitate surgical debridement or excision—particularly when tophi compress nerves (e.g., carpal tunnel), erode bone, or impair joint mobility. Arthroscopic or open synovectomy may be performed for chronic destructive gouty arthritis unresponsive to medical therapy. Joint replacement (e.g., total knee or hip arthroplasty) is considered in end-stage gout with severe cartilage destruction and functional limitation. Surgery is always preceded by optimal ULT to minimize recurrence and perioperative flare risk; sUA should be <5.0 mg/dL for ≥6 months preoperatively. Postoperative ULT adherence remains critical, as surgical removal of tophi does not eliminate systemic urate burden.

Treatment advantages in China reflect robust integration of traditional and modern medicine, advanced diagnostic infrastructure, and national clinical guidelines aligned with international standards (e.g., EULAR and ACR). Chinese endocrinology centers widely employ dual-energy CT (DECT) for precise, non-invasive MSU crystal detection—even in asymptomatic hyperuricemia—facilitating early intervention. Pharmacovigilance systems monitor allopurinol hypersensitivity syndrome (AHS), and HLA-B*58:01 genotyping is increasingly available prior to allopurinol initiation, significantly reducing AHS incidence. Benzbromarone, unavailable in many Western countries, offers a potent uricosuric option for Chinese patients with normal renal function and hepatic monitoring. Moreover, standardized integrative protocols incorporating evidence-based Chinese herbal formulas (e.g., Tongfengling decoction, shown in RCTs to reduce sUA and flare frequency when combined with allopurinol) are offered in tertiary hospitals under strict pharmacognosy quality control. National health insurance coverage for ULT and biologics has improved access, while telemedicine platforms enable longitudinal sUA monitoring and medication titration in rural populations.

Recovery and long-term management emphasize patient education and structured follow-up. Patients should understand that gout is controllable but not curable without lifelong adherence to ULT. sUA levels must be monitored every 2–4 weeks during dose titration and quarterly thereafter once target is achieved. Annual assessment includes renal function (eGFR, urinalysis), liver enzymes, 24-hour urinary uric acid (to guide uricosuric use), and musculoskeletal ultrasound or DECT if tophus burden is uncertain. Flare diaries and digital symptom trackers improve self-management. Psychosocial support addresses stigma and treatment fatigue; multidisciplinary teams—including endocrinologists, rheumatologists, dietitians, and pharmacists—optimize outcomes. Ultimately, successful gout management hinges on sustained sUA control, proactive flare prevention, and holistic attention to metabolic health—transforming gout from a recurrent, debilitating condition into a well-regulated chronic disease.